Exelixis (Nasdaq: EXEL) reported that its phase 3 STELLAR-303 trial evaluating zanzalintinib combined with atezolizumab in metastatic colorectal cancer did ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE